Y.ora Vision and Eyexora Global Partner with SERI to Advance New MIGS Platform for Glaucoma

Y.ora Vision, a newly formed ophthalmic medical device company, announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a next-generation minimally invasive surgical device for the treatment of mild-to-severe open-angle glaucoma (OAG).

The licensed technology, developed by Associate Professor Shamira Perera and Professor Michael Belkin at SERI, serves as the foundation for Y.ora Vision’s proprietary platform (YRA-01). This minimally invasive glaucoma surgery (MIGS) system is designed to perform multiple trabeculotomies in a single procedure—lowering IOP safely and effectively, without the need for permanent implants.

YRA-01 is a hand-held, implant-free device intended to integrate seamlessly with existing ophthalmic surgical equipment. The device enables surgeons to perform multiple micro-perforations in the trabecular meshwork in under 10 minutes, offering real-time feedback and potentially repeatable IOP-lowering outcomes. The extent of IOP reduction may be titrated based on the number of penetrations created, giving surgeons an unprecedented degree of control and flexibility.

“Glaucoma continues to rob millions of their sight despite decades of therapeutic and device-based advances,” said Huan Sheng, MD, PhD, Chief Medical Officer, Eyexora. “Our goal is to empower all ophthalmic surgeons with a reliable, minimally invasive, and user-friendly tool that achieves meaningful pressure reduction without the complications or cost of traditional implants. We have designed it with the expectation that surgeons will experience a short learning curve, enabling them to more confidently offer this solution to their patients.”

“This innovation builds upon years of work at SERI as well as clinical expertise in MIGS and reflects our commitment to translational research that directly improves patient outcomes,” said Associate Professor Shamira Perera, MD, Co-Inventor and Head & Senior Consultant, Glaucoma Department, Singapore National Eye Centre. “The simplicity of the device enables precise and easy tissue removal with minimal collateral trauma, making it a compelling new option for glaucoma and cataract surgeons alike.”